Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Genitourinary 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Neuroendocrine 5Neuroendocrine Tumors 3Lung Neoplasms 3Thyroid Carcinoma, Anaplastic 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Vulvar Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Gallbladder Neoplasms 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Bile Duct Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma, Mucinous 1Adenocarcinoma 1

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × atezolizumab × Endocrine × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡